Axsome Therapeutics Gains On Acquisition Of Sunosi From Jazz Pharma

'Something Elon can't do': CEO's dance moves light up the internet

New York (CNN Business)Elon Musk says he has Covid for a second time, but he is feeling relatively well.

In a tweet early Monday, the CEO of Tesla (TSLA) and SpaceX said he “supposedly have it again (sigh), but almost no symptoms.”
He previously tested positive for Covid in November 2020, before a vaccine was available, leading him to quarantine during a launch of four astronauts to the International Space Station aboard a SpaceX rocket.

    Musk has raised many questions about public health policy involving Covid since the disease was first discovered. But he has said he supports vaccination, even if he doesn’t believe the shots should be mandated.

      “To be clear, I do support vaccines in general & covid vaccines specifically. The science is unequivocal,” he tweeted back in April of last year.

      When he was named Time magazine’s Person of the Year in December he told the magazine he and his family were vaccinated. People who are vaccinated generally come down with less serious cases of the disease, and the majority of people who die from Covid are unvaccinated.

        In his tweet Monday, Musk questioned whether some of the current variants of Covid should still be considered Covid-19, a number assigned to the virus because it was first discovered in 2019.

          “How many gene changes before it’s not Covid-19 anymore?” he asked.

          Russia Intensifies Bombing In Ukrainian Cities

          As Russian forces intensified bombing around the suburbs of Ukrainian capital Kyiv, Deputy Defense Minister accused Russia of trying to establish a “corridor” around the city to disrupt supply routes.

          Shelling was reported in the cities of Lutsk, Kharkiv, Zhytomyr, Rivne and the outskirts of Kyiv Sunday evening, according to a presidential adviser.

          In anticipation of possible attacks by Russian forces, Ukraine says it won’t open humanitarian corridors from its cities on Monday.

          Corridors had been set up to allow civilians to leave some towns that are surrounded by Russian forces.

          Mariupol’s mayor has said the besieged port city must be completely evacuated as it is on the verge of humanitarian catastrophe.

          President Volodymyr Zelensky signaled that Ukraine is prepared to discuss adopting a neutral status if the fighting stopped.

          Zelensky said in an interview with independent Russian media that the suggestion, as part of a peace deal, needs to be approved in a referendum and be guaranteed by third parties.

          Russian Foreign Minister Sergey Lavrov said the next round of offline bi-lateral peace talks are scheduled to resume in Istanbul, Turkey, on Tuesday.

          Meanwhile, Dutch brewer Heineken has become the latest Western firm to stop its operations in Russia in protest against their invasion of Ukraine.

          Poly Surges 50% As HP Agrees To Buy The Co. In A $3.3 Bln Deal

          Shares of Poly, formerly known as Plantronics Inc., (POLY) surged nearly 50% on Monday morning after HP agreed to buy Plantronics in a $3.3 billion deal.

          POLY is currently trading at $39.28, up $13.08 or 49.94%, on the Nasdaq.

          HP announced a definitive agreement to acquire Poly, a provider of workplace collaboration solutions, in an all-cash transaction for $40 per share, implying a total enterprise value of $3.3 billion, inclusive of Poly’s net debt.

          The acquisition accelerates HP’s strategy to create a more growth-oriented portfolio, further strengthens its industry opportunity in hybrid work solutions, and positions the company for long-term sustainable growth and value creation.

          Intrepid Potash Down 8%

          Intrepid Potash, Inc. (IPI) shares are sliding more than 8 percent on Monday morning after reaching a five-year high on March 21. There were no corporate announcements on the day to influence the stock movement.

          The shares have been surging for the last several weeks since it reported fourth-quarter profit, compared to loss in the prior year.

          Currently, shares are at $82.13, down 8 percent from the previous close of $89.27 on a volume of 262,113. The shares have traded in a range of $22.82-$93.87 on average volume of 366,395.

          Sonos Gains 9% As The Co. Is Set To Join S&P SmallCap 600

          Shares of Sonos, Inc. (SONO) gained over 9% on Monday morning. SONO is currently trading at $28.92, up $2.46 or 9.30%, on the Nasdaq.

          Sonos is set to replace Chart Industries in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, March 30.

          Chart Industries Inc. (GTLS) will replace CyrusOne Inc. (CONE) in the S&P MidCap 400, as Global Infrastructure Partners has acquired CyrusOne.

          Volta Stock Tanks 16% As CEO Scott Mercer Resigns

          Shares of Volta Inc. (VLTA) are slipping over 16% on Monday morning after the company announced that founder Scott Mercer resigned as Chief Executive Officer.

          VLTA is currently trading at $3.46, down $0.67 or 16.2228%, on the Nasdaq.

          Mercer resigned as Chief Executive Officer, but will continue in that role for a transitional period and will serve as an advisor to the Board through March 31, 2023 and assist the Board in a search for a new CEO.

          Mercer is also resigning from the Board, effective immediately.

          Scott Mercer, Founder and departing CEO, said, “I am incredibly proud of Volta and what this team has achieved so far, and I am truly excited for its next phase of growth as the industry accelerates and matures. Volta was started with the ambition to be the best business model in the EV charging space, and now the company’s focus needs to turn to scaled, public-market-facing growth.”

          Axsome Therapeutics Gains On Acquisition Of Sunosi From Jazz Pharma

          Axsome Therapeutics, Inc. (AXSM) shares are progressing on Monday morning trade after the company said it plans to acquire Sunosi from Jazz Pharmaceuticals. Sunosi is the first dual-acting dopamine and norepinephrine reuptake inhibitor approved by the FDA.

          The acquisition is expected to be immediately revenue-generating and expected to be breakeven to the operating plan in 2023, and substantially accretive thereafter. Further, the combination will help accelerate the transformation of the company into a global commercial entity. Axsome expects to launch AXS-05 for depressive disorder and AXS-07 for migraine.

          The shares are currently at $36.94, up 5 percent from the previous close of $35.36 on a volume of 592,261. For the 52-week period the shares have traded in a range of $19.38-$74.10 on average volume of 856,163.